[Pathophysiological implication of the VPAC2 receptor in psychiatric disorders]

Area of Science:

• Neuroscience
• Genetics
• Psychiatry

Background:

• The genomic era reveals gene and pathway links to schizophrenia and autism spectrum disorder (ASD).
• Microduplications at 7q36.3, including the VIPR2 gene, are implicated as risk factors for schizophrenia and are increased in ASD.
• VIPR2 encodes the VPAC2 receptor, a G protein-coupled receptor binding PACAP and VIP neuropeptides.

Purpose of the Study:

• To review recent advances in the genetics of schizophrenia.
• To discuss the potential pathophysiological role of altered VPAC2 signaling in psychiatric disorders, including schizophrenia and ASD.

Main Methods:

• Review of existing genetic studies on schizophrenia and ASD.
• Analysis of the VIPR2 gene and its encoded VPAC2 receptor function.
• Exploration of potential mechanisms linking VPAC2 signaling to psychiatric disorders.

Main Results:

• Clinical studies demonstrate a genetic linkage between VIPR2 and schizophrenia/ASD.
• VIPR2 microduplications are identified as a risk factor for schizophrenia and are elevated in ASD.
• VPAC2 signaling is implicated in the etiology of these mental health disorders.

Conclusions:

• VIPR2 represents a potential novel biomarker and therapeutic target for schizophrenia and ASD.
• Further research is needed to elucidate the precise mechanisms of VPAC2 signaling in psychiatric disorders.
• Understanding VIPR2's role may offer new insights into the pathophysiology of schizophrenia and ASD.